Sugi Predict

Sugi Predict / Targets / PDE4B

PDE4B

3',5'-cyclic-AMP phosphodiesterase 4B · Q07343 · PDE4B on Sugi Atlas →

326,949 patent compounds predicted against PDE4B, 160,483 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Roflumilast Roflumilast (SCHEMBL19158) 1.00 20/20
Cilomilast Cilomilast (SCHEMBL26372) 1.00 20/20
Cilomilast Cilomilast (SCHEMBL27515) 1.00 20/20
Cilomilast Cilomilast (SCHEMBL27516) 1.00 20/20
SCHEMBL84865 SCHEMBL84865 1.00 20/20
SCHEMBL84940 SCHEMBL84940 0.69 19/20
SCHEMBL71069 SCHEMBL71069 0.59 19/20
SCHEMBL73157 SCHEMBL73157 0.56 19/20
SCHEMBL74891 SCHEMBL74891 0.63 18/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL74285) 0.59 18/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL74596) 0.58 18/20
SCHEMBL85519 SCHEMBL85519 0.56 18/20
SCHEMBL73048 SCHEMBL73048 0.54 18/20
SCHEMBL92660 SCHEMBL92660 0.54 18/20
SCHEMBL73156 SCHEMBL73156 0.53 18/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL72328) 0.49 18/20
SCHEMBL84902 SCHEMBL84902 0.45 18/20
SCHEMBL71427 SCHEMBL71427 0.66 17/20
SCHEMBL72686 SCHEMBL72686 0.66 17/20
SCHEMBL73260 SCHEMBL73260 0.64 17/20

Clinical trials — most relevant to PDE4B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis PHASE4COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes PHASE3RECRUITING
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients PHASE1/PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Effect of Tadalafil on Cerebral Large Arteries in Stroke PHASE2COMPLETED
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients PHASE2COMPLETED
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome PHASE1/PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET PHASE1RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients PHASE1COMPLETED
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. nanUNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE4B binder may also engage these)

ProteinNameSimilarity
P14646 — 1.000 P14646 →
Q01063 — 1.000 Q01063 →
P14270 — 1.000 P14270 →
O89084 — 1.000 O89084 →
PDE4D 3',5'-cyclic-AMP phosphodiesterase 4D 0.999 landscape →
P54748 — 0.997 P54748 →
F4JZ68 — 0.997 F4JZ68 →
PDE4C 3',5'-cyclic-AMP phosphodiesterase 4C 0.997 landscape →
P30645 — 0.995 P30645 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.995 landscape →
PDE4A 3',5'-cyclic-AMP phosphodiesterase 4A 0.994 landscape →
H2QL32 — 0.994 H2QL32 →
Q92539 — 0.994 Q92539 →
Q6NRL1 — 0.994 Q6NRL1 →
A6NIR3 — 0.994 A6NIR3 →
G5EFD2 — 0.994 G5EFD2 →
B3H6Z8 — 0.993 B3H6Z8 →
Q9AWM8 — 0.993 Q9AWM8 →
Q22000 — 0.993 Q22000 →
Q6DBX4 — 0.993 Q6DBX4 →
F4JX00 — 0.993 F4JX00 →
F7E540 — 0.993 F7E540 →
Q5VW22 — 0.993 Q5VW22 →
Q96P64 — 0.993 Q96P64 →
Q9XYB7 — 0.993 Q9XYB7 →
PDE9A High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A 0.993 landscape →
Q8IRU4 — 0.993 Q8IRU4 →
Q5VUJ5 — 0.993 Q5VUJ5 →
Q66HD5 — 0.993 Q66HD5 →
A8WRV1 — 0.993 A8WRV1 →